Partnering & deal-making

Project Challenge: Our client was a company on which we had conducted due diligence for an investor approached us for support with a potential deal with an AI discovery company. The concept was to...

Challenge: A medical device company has developed a nebulizer system for pulmonary delivery that can produce droplets below 1.5µm diameter. Initial clinical evaluations of demonstrator compounds used...

Challenge: A biotech company focusing in fibrosis and autoimmunity was planning a reverse takeover transaction with a listed entity and required support in formulating its proxy statement (investor...

Challenge A company was developing a unique dengue vaccine which it planned to out-license to a Big Pharma partner. Alacrita was commissioned to provide business development support to identify a...

Challenge Our client, a mid-cap research-based pharmaceutical company, had enjoyed striking success with a rare disease product which had different market dynamics to the bulk of the company's...

Challenge A biotech company focused on developing therapeutics for oncology indications was looking to contract a clinical consultant to support their in-house team in presenting its technology and...

Challenge: An investor group was facing its first potential deal in the pharmaceuticals sector. It had pre-negotiated a deal with a group that had invented an approach to treating...

Project Challenge: An early stage investor was in the midst of setting up a NewCo for the research and development of novel treatments using a fairly under-researched area of cell biology. However, a...

Alacrita provides support to organizations seeking pharmaceutical licensing opportunities, both in- and out-licensing, as well as negotiation support. Our approach is flexible and can be tailored...

Challenge: In order to better review potential acquisition and licensing opportunities, a pharma company asked Alacrita to landscape the companies, medical devices, digital technologies, research...

Challenge: A biotechnology company developing novel multi-specific antibody therapeutics to treat a range of cancers asked Alacrita to develop valuations for its four leading assets, as well as...

Challenge A private biotech company developing gene therapy products for several orphan diseases was in the process of initiating CMC development for their pipeline products. In order to move...